文献速递眼底病与葡萄膜炎

AREDS AMD量表2年进展与晚期年龄相关性黄斑变性或视力丧失的关联:AREDS报告41

Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity: AREDS Report 41.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

本研究基于AREDS队列,评估AREDS AMD量表2年进展(≥2步或≥3步增加)是否可预测5年内进展为晚期AMD或最佳矫正视力(BCVA)丧失。结果显示2年进展与新生血管性AMD、地图样萎缩及视力丧失均显著相关,且≥3步进展关联更强,提示该量表可用于未来临床试验。

要点

  • AREDS AMD量表2年进展≥2步或≥3步与5年内晚期AMD风险显著相关。
  • ≥3步进展的关联强度高于≥2步进展。
  • 2年进展也与BCVA丧失≥2行或≥3行相关。

核心结论

  • AREDS AMD量表2年进展与晚期AMD及视力丧失等临床有意义结局相关,可能有助于未来减缓AMD进展的临床试验。

研究设计与样本

  • AREDS为随机安慰剂对照临床试验,纳入3868名基线无晚期AMD的参与者,每年中央判读彩色眼底照片。
  • 评估基线至2年访视时AMD评分≥2步和≥3步增加对长期结局的预测价值,随访5年(第2-7年)。

主要发现

  • 2年内669/7458只眼(9.0%)≥2步进展,275/7458只眼(3.7%)≥3步进展。
  • 5年随访中,486/7223只眼(6.7%)发生新生血管性AMD,339/7253只眼(4.7%)发生中心性地图样萎缩,726/7246只眼(10.0%)发生任何地图样萎缩。
  • 5年随访中,2622/7095只眼(37.0%)BCVA丧失≥2行,1494/7155只眼(20.9%)BCVA丧失≥3行。
  • 调整混杂因素并按基线AMD评分分层后,2年进展与新生血管性AMD风险显著相关,HR范围3.6(99% CI 2.4-5.2)至19.4(99% CI 7.7-48.9)。
  • 2年进展与中心性地图样萎缩(HR 2.6-4.7)、任何地图样萎缩(结果相似)及BCVA丧失(HR 1.3-2.8)也显著相关,≥3步进展关联更强。

关键数值与推荐

  • 2年进展定义为基线至2年访视AMD评分增加≥2步或≥3步。
  • 主要结局包括新生血管性AMD、中心性地图样萎缩、任何地图样萎缩、BCVA丧失≥2行或≥3行。
  • 新生血管性AMD的HR范围3.6(99% CI 2.4-5.2)至19.4(99% CI 7.7-48.9)。
  • 中心性地图样萎缩的HR范围2.6(99% CI 1.7-4.0)至4.7(99% CI 2.5-8.9)。
  • BCVA丧失的HR范围1.3(99% CI 1.0-1.7)至2.8(99% CI 1.8-4.3)。

临床怎么用

  • 可将AREDS AMD量表2年进展作为临床试验或流行病学研究中估计长期进展风险的指标。
  • ≥3步进展可能比≥2步进展提供更强的风险分层信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Age-Related Eye Disease Study age-related macular degeneration (AREDS AMD) scale is designed to classify AMD severity. The present cohort study explored whether 2-year progression along this scale was useful for estimating the risk of future progression to late AMD or best-corrected visual acuity (BCVA) loss. OBJECTIVE: To assess whether 2-year progression along the AREDS AMD scale can be used to estimate the probability of long-term clinically meaningful outcome measures for clinical trials or epidemiologic studies. DESIGN, SETTING, AND PARTICIPANTS: Age-Related Eye Disease Study participants enrolled in a clinical trial of oral micronutrient supplements had annual color fundus photographs graded centrally using the AREDS AMD scale. Two-year progression (≥2-step and ≥3-step increases in AMD score between baseline and the 2-year study visit) was evaluated as a method of estimating the risk of long-term progression to late AMD or BCVA loss. The AREDS (1992-2001) was a randomized, placebo-controlled clinical trial based at 11 retinal specialty clinics in the United States. The dates of analysis in the present cohort study were November 1992 through November 2005. MAIN OUTCOMES AND MEASURES: Development of neovascular (NV) AMD, central geographic atrophy (CGA), any geographic atrophy (GA), or BCVA loss of at least 2 lines or at least 3 lines. RESULTS: Among 3868 participants in the AREDS free of late AMD at baseline, the mean (SD) age was 68.3 (5.0) years, and 2180 of 3868 (56.4%) were women. In the first 2 years after randomization to the AREDS, 669 of 7458 (9.0%) of eyes had at least 2-step 2-year progression, and 275 of 7458 (3.7%) of eyes had at least 3-step 2-year progression. In the 5-year follow-up period (years 2-7), 486 of 7223 (6.7%) of eyes developed NV AMD, 339 of 7253 (4.7%) developed CGA, 726 of 7246 (10.0%) developed any GA, 2622 of 7095 (37.0%) had at least 2-line BCVA loss, and 1494 of 7155 (20.9%) had at least 3-line BCVA loss. After adjusting for demographic and clinical confounders and stratifying by baseline AMD score, statistically significant associations were observed between at least 2-step and at least 3-step 2-year progression of AMD score and subsequent 5-year development of NV AMD: hazard ratios (HRs) ranged from 3.6 (99% CI, 2.4-5.2) to 19.4 (99% CI, 7.7-48.9). For CGA, HRs ranged from 2.6 (99% CI, 1.7-4.0) to 4.7 (99% CI, 2.5-8.9); the results were similar for any GA. For at least 2-line and at least 3-line BCVA loss, HRs ranged from 1.3 (99% CI, 1.0-1.7) to 2.8 (99% CI, 1.8-4.3). For all outcomes, at least 3-step 2-year progression had stronger associations than at least 2-step 2-year progression. These findings were also validated in the AREDS2 cohort. CONCLUSIONS AND RELEVANCE: Two-year progression of AMD score was associated with progression to clinically meaningful anatomic (late AMD) and vision (≥2-line or ≥3-line loss) outcomes, suggesting that this scale may be useful for future clinical trials designed to slow the progression of AMD.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Vitale S, Agrón E, Clemons TE, et al. Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity: AREDS Report 41. JAMA Ophthalmol. 2020. PMID: 32271358. doi:10.1001/jamaophthalmol.2020.0824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。